Epoch Life Science

Company Overview

Epoch Life Science Inc., founded in 2002, is a molecular-biology reagents company with an emphasis on nucleic acid purification kits, modifying enzymes, cytokines, antibodies, and DNA synthesis. Epoch provides gene-synthesis services that include fragment synthesis, cloning, codon optimization, and sequence verification. The company is a second-tier competitor in the gene synthesis market and its total annual sales are estimated to be less than $5 million.

Epoch is positioning its gene synthesis service as an alternative to cloning among its academic and industrial research customers. The company emphasizes cost savings by eliminating the messenger RNA (mRNA) extraction, reverse transcription (RT)-PCR, and cloning or sub-cloning steps. Potential cost savings over conventional cloning based on Epoch’s synthesis pricing structure are 33% for a 2 kb, less than 10 copies, lower than 50% GC (guanine-cytosine) sequence.

Company's Business Segments

• Biotechnology and Pharmaceuticals : The company offers a variety of reagents and services for academic research and pharmaceutical drug discovery, focusing on gene synthesis, gene optimization, and DNA purification.